LH vs MRNA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LH · Labcorp Holdings$366.57 ▲ 0.90%
MRNA · Moderna$254.19 ▲ 5.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LH +41.8%
- MRNA +926.6%
Head to head
| Metric | LH | MRNA |
|---|---|---|
| Price | $366.57 | $254.19 |
| Change today | ▲ 0.90% | ▲ 5.27% |
| Market cap | $29.77B | $101.48B |
| Return, 3 months | +14.3% | +325.0% |
| Return, year to date | +47.2% | +762.0% |
| Return, 1 year | +46.5% | +935.8% |
| P/E (TTM) | 30.0 | – |
| P/B | 3.4 | 15.0 |
| P/E percentile vs own 5y | 75th | 1st |
| Dividend yield | 0.79% | – |
| Revenue growth (YoY, latest qtr) | +6.9% | +4.4% |
| Net profit growth (YoY) | +0.6% | +5.2% |
| Gross margin | 29.0% | 22.8% |
| Operating margin | 11.3% | -150.2% |
| Net margin | 6.9% | -142.6% |
| Return on equity | 11.4% | -39.0% |
| Analyst target vs. price | +6.7% | -42.3% |
| Analyst buy share | 91% | 15% |
| RSI (14) | 70 | 64 |
| 30-day volatility | 31.4% | 101.4% |
| Max drawdown, 1 year | -13.4% | -34.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRNA is the largest of the group by market value.
- MRNA has returned the most over the past year.
- LH is growing revenue fastest.
- LH keeps the most profit per dollar of sales.
- LH has been the calmest stock over the last 30 days.